×
RAPS Learning Portal will be under maintenance on 12 June 2026 between 10 PM - 12 AM ET. Learning Portal functionality and profile access may be unavailable during this window.
We apologize for any inconvenience caused during this time.

rf-fullcolor.png

 

26 June 2012
by Alexander Gaffney, RAC

Citing a Change in Thinking, FDA Withdraws Lupus Product Guidance

The US Food and Drug Administration (FDA) said it is withdrawing a guidance document published in June 2010 in light of the document no longer reflecting its current thinking on the topic.

In its 26 June 2012 Federal Register posting, FDA said its guidance, "Lupus Nephritis Caused by Systemic Lupus Erythematosus-Developing Medical Products for Treatment," was being withdrawn immediately.

Systemic Lupus Erythamatosus is an autoimmune disease in which the body's immune system attacks cells and tissues within the body. This can cause a condition known as lupus nephritis, which is characterized by the inflammation of the kidney. FDA did not offer any explanation as to why it was withdrawing the guidance, and what could have changed between June 2010 and June 2012 to differently inform its thought process.

There are no public comments listed in the Regulations.gov web docket for the 2010 notice, implying FDA came to its decision by its own accord or through non-public comments.


Read more:

FDA - Guidance for Industry; Withdrawal: Lupus Nephritis Caused By Systemic Lupus Erythematosus--Developing Medical Products for Treatment